- “We provide a pre-forwarded antibody to someone who has been infected before so that the antibody can combat the virus,” Dr. Rana explained.
- The use of convalescent plasma has been removed from the recommended treatment protocols for the novel coronavirus, according to recent ICMR guidelines.
- Remdesivir was approved for limited emergency use in June of last year to treat Covid-19 patients.
Following an Indian Council of Medical Research (ICMR) guideline for the use of convalescent plasma in the treatment of coronavirus patients, Ganga Ram Hospital Chairperson Dr. DS Rana has stated that Remdesivir could be phased out of COVID-19 treatment in the coming days.
There is no proof of its efficacy in treating COVID-19 patients, according to Dr. Rana. According to an advisory from the Indian Council of Medical Research (ICMR), the use of convalescent plasma has been removed from the recommended treatment protocols for COVID-19.
Dr. DS Rana, Chairman of Ganga Ram Hospital, told ANI, “In plasma therapy, we give someone who has already been infected a pre-forwarded antibody so that it can combat the virus. When the coronavirus attacks, antibodies usually form.”
Dr. Rana elaborated, “We’ve noticed in the last year that giving plasma has no effect on the patient’s or other people’s health. It’s also not easily available. Plasma therapy started on a scientific basis and has since been phased out due to evidence.”
Dr. Rana claims that “When it comes to other medications used in COVID treatment, there is no proof that Remdesivir works in Covid-19 treatment. Medicines that don’t have any activity to work will have to be stopped.”
“If no evidence of their efficacy can be found, all experimental drugs, including plasma therapy (which has since been discontinued) and Remdesivir, may be phased out quickly. Just three medicines are currently effective “, said Dr. Rana.
“Right now, we are investigating and keeping an eye on things. The medical community is attempting to gather more data; however, I believe the pandemic will be over by the time you have complete knowledge of it “He said.
On Monday, the ICMR announced that convalescent plasma could no longer be used in COVID-19 treatment protocols. With the number of cases increasing across the country, there has been a surge in demand for plasma donors, despite experts’ reservations about plasma therapy’s efficacy for Covid-19 patients.
Meanwhile, the Indian Medical Association (IMA) endorsed plasma therapy in moderate cases of COVID-19 infection, claiming that such patients would need less oxygen if plasma was used.
The IMA approved plasma therapy only one day after the National Task Force (NTF) of ICMR advised against using convalescent plasma therapy in the COVID-19 treatment protocol.
Remdesivir was permitted for limited emergency use in India for the treatment of coronavirus positive patients in June of last year. Only hospitals and pharmacies are allowed to store it, and it can only be purchased in the form of an injection with a prescription.